image credit- shutterstock
Japan-based Chugai Pharmaceutical has announced the establishment of a new partnering office in South San Francisco, US. The office will operate as a branch of Chugai’s wholly-owned subsidiary, Chugai Pharma USA, Inc.(CPUSA), and will begin operations in January 2026.
Chugai aims to become a top innovator in the global healthcare industry by 2030, and positions open innovation as one of the key drivers to achieve this goal. Through the establishment of Chugai Partnering US Office, headed by Andrew Wong, who has held key business development positions at leading global pharmaceutical companies and research institutions, Chugai will strengthen its network with the academia and startups in the US, while advancing strategic external partnership activities.
Chugai Partnering US Office will also collaborate with Chugai’s partnering functions across multiple regions to accelerate global open innovation. Chugai’s head office (Japan) along with its wholly-owned subsidiaries, Chugai Pharma Europe Ltd. (UK) and Chugai Pharmabody Research Pte. Ltd., have been advancing partnerships with local companies and research institutions.
With the establishment of Chugai Partnering US Office, Chugai will further strengthen this global partnering network and establish a comprehensive framework for worldwide partnership activities. Moreover, along with investment activities in external startups and cutting-edge technologies via the Chugai Venture Fund (Boston, US) , Chugai will aim to drive further innovation.
